Showing results (91-100 of 123) with videos related to

Sort By:
Pageof 13
The Journal of Antimicrobial Chemotherapy|April 27, 2023
Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistanceSidonie Lambert-Niclot, Basma Abdi, Jonathan Bellet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 9, 2025
Antimicrobial drug-resistant Neisseria gonorrhoeae (GC) infections in men using doxycycline postexposure prophylaxis. A substudy of the ANRS 174 DOXYVAC trialBéatrice Bercot, Lambert Assoumou, François Caméléna, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Infectious Diseases Now|July 16, 2023
Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19Nadir Arber, Pallav L Shah, Lambert Assoumou, et al.
The Lancet. HIV|May 15, 2026
Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trialRoland Landman, Lambert Assoumou, Sidonie Lambert-Niclot, et al.
The Journal of Antimicrobial Chemotherapy|November 30, 2017
Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trialPierre de Truchis, Lambert Assoumou, Roland Landman, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|March 15, 2024
High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022Romain Palich, Andrés Arias-Rodríguez, Martin Duracinsky, et al.
Journal for Immunotherapy of Cancer|August 23, 2024
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort studyLambert Assoumou, Raghiatou Baldé, Christine Katlama, et al.
The Journal of Antimicrobial Chemotherapy|June 17, 2008
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtideDiane Descamps, Lambert Assoumou, Bernard Masquelier, et al.
The Lancet. HIV|June 30, 2022
Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort studyJean-Michel Molina, Jade Ghosn, Lambert Assoumou, et al.
Pageof 13